Home » CARDIOME/ASTELLAS: FDA SETBACK FOR HEART DRUG
CARDIOME/ASTELLAS: FDA SETBACK FOR HEART DRUG
The FDA has refused to accept an application for a proposed treatment of atrial fibrillation. The approval of Cardiome's new treatment for atrial fibrillation is set to be delayed by almost a year after the FDA refused to file an application for the drug.
Pharmaceutical Business Review
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May